Show simple item record

dc.contributor.authorTimbrell, Simon
dc.contributor.authorAglan, Hosam
dc.contributor.authorCramer, Angela
dc.contributor.authorFoden, P.
dc.contributor.authorWeaver, D.
dc.contributor.authorPachter, J.
dc.contributor.authorKilgallon, Aoife
dc.contributor.authorClarke, Robert B
dc.contributor.authorFarnie, Gillian
dc.contributor.authorBundred, Nigel J
dc.date.accessioned2021-07-19T10:28:39Z
dc.date.available2021-07-19T10:28:39Z
dc.date.issued2021en
dc.identifier.citationTimbrell S, Aglan H, Cramer A, Foden P, Weaver D, Pachter J, et al. FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity. npj Breast Cancer. 2021 May 28;7(1). en
dc.identifier.pmid34050172en
dc.identifier.doi10.1038/s41523-021-00263-3en
dc.identifier.urihttp://hdl.handle.net/10541/624065
dc.description.abstractCancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant therapies. FAK inhibition reduced CSC activity and self-renewal across all molecular subtypes in primary human breast cancer samples. Combined FAK and paclitaxel reduced self-renewal in triple negative cell lines. An invasive breast cancer cohort confirmed high FAK expression correlated with increased risk of recurrence and reduced survival. Co-expression of FAK and CSC markers was associated with the poorest prognosis, identifying a high-risk patient population. Combined FAK and paclitaxel treatment reduced tumour size, Ki67, ex-vivo mammospheres and ALDH+ expression in two triple negative patient derived Xenograft (PDX) models. Combined treatment reduced tumour initiation in a limiting dilution re-implantation PDX model. Combined FAK inhibition with adjuvant therapy has the potential to improve breast cancer survival.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41523-021-00263-3en
dc.titleFAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activityen
dc.typeArticleen
dc.contributor.departmentBreast Biology Group, Manchester Breast Centre, Oglesby Cancer Research Building, University of Manchester, Manchester,en
dc.identifier.journalNPJ Breast Canceren
dc.description.noteen]
refterms.dateFOA2021-07-26T12:36:57Z


Files in this item

Thumbnail
Name:
34050172.pdf
Size:
7.353Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record